Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified ...

Grafting patches of lab-grown muscle to the surface of the heart could offer a lifeline for people waiting for a transplant.

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Leadership Perspective “Creative Medical is at the forefront of regenerative medicine, and our extended partnership with Greenstone Biosciences marks a significant milestone in our mission to develop ...

该研究也指出，由于DMD突变类型多样且分布广泛，单一ASO药物难以覆盖所有患者。尤其是针对深层内含子突变的修复，现有方法的效果仍然有限。此外，基因治疗的研发成本高昂，临床转化周期长，给患者的普及使用带来显著障碍。

The Ethical and Versatile Potential of Induced Pluripotent Stem Cells (iPSCs)Boston, Jan. 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Induced Pluripotent Stem Cells: ...

In "remarkable" work, a patch of engineered heart muscle cells was used to strengthen a patient's heart before transplant.

A woman with heart failure was kept alive long enough to receive a heart transplant, in part thanks to newly developed ...

This is especially problematic in cases of blocked blood vessels, which can repeatedly starve large areas of the heart of oxygen and nutrients, killing the cardiomyocytes there. This leads to a ...

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a ...

Following successful tests on rats and rhesus monkeys, the researchers studied their approach on a 46-year-old woman with ...